转移性胰腺癌:ASCO临床实践指南更新
ASCO召集专家小组系统综述2015年6月至2018年1月发表的二线治疗文献,纳入两项符合标准的新研究,据此更新转移性胰腺癌二线治疗推荐,并认可2016版指南其他主题推荐。更新明确不同一线方案后二线选择及错配修复缺陷/微卫星不稳定检测与帕博利珠单抗推荐。
要点
- 一线FOLFIRINOX后,ECOG PS 0-1且合并症良好者可选吉西他滨联合白蛋白结合型紫杉醇。
- 一线吉西他滨联合白蛋白结合型紫杉醇后,ECOG PS 0-1且合并症良好者可选氟尿嘧啶联合脂质体伊立替康。
- ECOG PS 2或合并症限制其他方案者选吉西他滨或氟尿嘧啶;推荐检测错配修复缺陷/微卫星不稳定。
核心结论
- 更新纳入二线治疗新证据并给出相应推荐,同时认可2016版指南其他主题推荐。
研究设计与样本
- ASCO召集专家小组对2015年6月至2018年1月发表的二线治疗文献进行系统综述,纳入两项符合标准的新研究。
主要发现
- 系统综述发现两项符合纳入标准的新研究,用于形成二线治疗推荐。
关键数值与推荐
- 一线FOLFIRINOX后,ECOG PS 0-1且合并症良好者应提供吉西他滨联合白蛋白结合型紫杉醇。
- 一线吉西他滨联合白蛋白结合型紫杉醇后,ECOG PS 0-1且合并症良好者可提供氟尿嘧啶联合脂质体伊立替康。
- 氟尿嘧啶联合脂质体伊立替康不可及时,可提供氟尿嘧啶联合伊立替康或氟尿嘧啶联合奥沙利铂。
- ECOG PS 2或合并症限制其他方案者,应提供吉西他滨或氟尿嘧啶。
- 推荐对选定患者检测错配修复缺陷或微卫星不稳定,错配修复缺陷或高微卫星不稳定肿瘤推荐帕博利珠单抗。
临床怎么用
- 按一线方案、ECOG PS和合并症选择二线方案,并检测错配修复缺陷/微卫星不稳定以指导免疫治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose In 2016, ASCO published a guideline to assist in clinical decision making in metastatic pancreatic cancer for initial assessment after diagnosis, first- and second-line treatment options, palliative and supportive care, and follow-up. The purpose of this update is to incorporate new evidence related to second-line therapy for patients who have experienced disease progression or intolerable toxicity during first-line therapy. Methods ASCO convened an Expert Panel to conduct a systematic review of the literature on second-line therapy published between June 2015 and January 2018. Recommendations on other topics covered in the 2016 Metastatic Pancreatic Cancer Guideline were endorsed by the Expert Panel. Results Two new studies were found that met the inclusion criteria. Recommendations For second-line therapy, gemcitabine plus nanoparticle albumin-bound paclitaxel should be offered to patients with first-line treatment with FOLFIRINOX (leucovorin, fluorouracil, irinotecan, and oxaliplatin), an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 1, and a favorable comorbidity profile; fluorouracil plus nanoliposomal irinotecan can be offered to patients with first-line treatment with gemcitabine plus NAB-paclitaxel, an ECOG PS of 0 to 1, and a favorable comorbidity profile; fluorouracil plus irinotecan or fluorouracil plus oxaliplatin may be offered when there is a lack of availability of fluorouracil plus nanoliposomal irinotecan; gemcitabine or fluorouracil should be offered to patients with either an ECOG PS of 2 or a comorbidity profile that precludes other regimens. Testing select patients for mismatch repair deficiency or microsatellite instability is recommended, and pembrolizumab is recommended for patients with mismatch repair deficiency or high microsatellite instability tumors. Endorsed recommendations from the 2016 version of this guideline for computed tomography, baseline performance status and comorbidity profile, defining goals of care, first-line therapy, and palliative care are also contained within the full guideline text. Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines .
引用
- Sohal DPS, Kennedy EB, Khorana A, et al. Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2018. PMID: 29791286. doi:10.1200/JCO.2018.78.9636
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。